Phillip D Stricker
Overview
Explore the profile of Phillip D Stricker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
2396
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gong T, Jiang J, Uthayopas K, Bornman M, Gheybi K, Stricker P, et al.
Nat Commun
. 2025 Mar;
16(1):2400.
PMID: 40064858
Prostate cancer (PCa) is highly heritable, with men of African ancestry at greatest risk and associated lethality. Lack of representation in genomic data means germline testing guidelines exclude for Africans....
2.
Yamaguchi T, Houlahan K, Zhu H, Kurganovs N, Livingstone J, Fox N, et al.
Cancer Discov
. 2025 Feb;
PMID: 39945744
Newly diagnosed prostate cancers differ dramatically in mutational composition and lethality. The most accurate clinical predictor of lethality is tumor tissue architecture, quantified as tumor grade. To interrogate the evolutionary...
3.
Geboers B, Scheltema M, Jung J, Bakker J, Timmer F, Cerutti X, et al.
BJU Int
. 2024 Aug;
135(2):319-328.
PMID: 39101639
Objectives: To prospectively compare systemic anti-tumour immune responses induced by irreversible electroporation (IRE) and robot-assisted radical prostatectomy (RARP) in patients with localised intermediate-risk prostate cancer (PCa). Patients And Methods: Between...
4.
Huang R, Bornman M, Stricker P, Simoni Brum I, Mutambirwa S, Jaratlerdsiri W, et al.
Sci Rep
. 2024 Apr;
14(1):7706.
PMID: 38565642
The telomere repetitive TTAGGG motif at the ends of chromosomes, serves to preserve genomic integrity and chromosomal stability. In turn, genomic instability is a hallmark of cancer-implicating telomere disturbance. Prostate...
5.
Geboers B, Scheltema M, Emmett L, Stricker P
BJU Int
. 2024 Feb;
133 Suppl 4:25-26.
PMID: 38419354
No abstract available.
6.
Gondoputro W, Doan P, Katelaris A, Scheltema M, Geboers B, Agrawal S, et al.
Transl Androl Urol
. 2023 Nov;
12(10):1598-1606.
PMID: 37969779
Background: In active surveillance there is significant interest in whether imaging modalities such as multiparametric magnetic resonance imaging (mpMRI) or Gallium prostate-specific membrane antigen positron emission tomography/computerized tomography (Ga-PSMA-PET/CT) can...
7.
Geboers B, Meijer D, Counter W, Blazevski A, Thompson J, Doan P, et al.
BJU Int
. 2023 Oct;
133 Suppl 4:14-22.
PMID: 37858931
Objective: To evaluate the additional value of prostate-specific membrane antigen positron emission tomography (PSMA-PET) to conventional diagnostic tools to select patients for hemi-ablative focal therapy (FT). Patients And Methods: We...
8.
Craddock J, Jiang J, Patrick S, Mutambirwa S, Stricker P, Bornman M, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444571
Prostate cancer is driven by acquired genetic alterations, including those impacting the epigenetic machinery. With African ancestry as a significant risk factor for aggressive disease, we hypothesize that dysregulation among...
9.
Deivasigamani S, Kotamarti S, Rastinehad A, Salas R, de la Rosette J, Lepor H, et al.
Eur Urol
. 2023 Jul;
84(6):547-560.
PMID: 37419773
Context: Whole-gland ablation is a feasible and effective minimally invasive treatment for localized prostate cancer (PCa). Previous systematic reviews supported evidence for favorable functional outcomes, but oncological outcomes were inconclusive...
10.
Li L, Shiradkar R, Tirumani S, Bittencourt L, Fu P, Mahran A, et al.
Eur J Radiol Open
. 2023 Jul;
10:100496.
PMID: 37396490
Background: around one third of clinically significant prostate cancer (CsPCa) foci are reported to be MRI non-visible (MRI─). Objective: To quantify the differences between MR visible (MRI+) and MRI CsPCa...